India To Act On Chinese Drug
India's Commerce Ministry's anti-dumping authority has recommendedantidumping duties against imports of 8-hydroxyquinoline from China.
The authority says that the product is being imported at prices below its normal value, and that the domestic industry has suffered material injury. Therefore, it recommends anti-dumping duties of 183 rupees ($5.10) per kilo against Sinochem Jiangsu Import and Export Corp, and of 206 rupees ($5.75) per kilo against China Jiangsu Medicines and Health Products Import and Export (Group) Corp of China, and for all exporters of the product from China.
India imported 14.5 million tonnes of 8-hydroxyquinoline from China from April 1994 to March 1995, and 22 million tonnes in the first four months of 1995-96.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze